Codexis, Inc. — FY2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016. The filing is an annual report, not a standalone fourth-quarter filing; quarterly figures are noted where relevant. Codexis engineers and sells enzymes and related services, primarily for pharmaceutical manufacturing, using its CodeEvolver protein-engineering platform.
Financial performance and liquidity
| Metric | FY2016 | FY2015 |
|---|---|---|
| Total revenue | $48.8 million | $41.8 million |
| Product sales | $15.3 million | $11.4 million |
| Research and development revenue | $31.3 million | $25.6 million |
| Revenue-sharing income | $2.2 million | $4.8 million |
| Operating loss | $8.6 million | $7.8 million |
| Net loss | $8.6 million; $0.21 per share | $7.6 million; $0.19 per share |
| Cash used in operations | $2.7 million | $0.4 million |
| Cash and cash equivalents at year-end | $19.2 million | $23.3 million |
| Working capital at year-end | $14.9 million | $18.0 million |
- Product gross margin was 36% in 2016, down from 42% in 2015. Management attributed the decline to a greater share of lower-margin sitagliptin enzyme sales to Merck and fewer higher-margin fine-chemicals sales.
- Total assets were $35.6 million and total liabilities were $16.5 million at year-end. The balance sheet does not report borrowings or a debt balance; liabilities include deferred revenue and lease-related obligations.
- Cash, cash equivalents and short-term investments were reported as $19.2 million in selected financial data. Separately, the balance sheet lists $1.1 million of marketable securities and $1.6 million of restricted cash.
- Cash declined by $4.0 million during 2016. Cash used in investing activities was $0.8 million and cash used in financing activities was $0.5 million.
Material changes and notable quarterly results
- Revenue increased 17% year over year. Product sales rose 35%, principally on higher demand, including Merck sitagliptin enzyme sales.
- R&D revenue rose 22%, supported by completion of the final CodeEvolver technology-transfer milestones for Merck ($8.0 million) and GSK ($7.5 million) and recognition of previously deferred license revenue as transfers finished earlier than expected. These milestone and transfer-related amounts are not necessarily recurring.
- Revenue-sharing income fell 54% as generic competition increased following expiration of the argatroban formulation patent in June 2014; management expected this revenue could continue to decline.
- R&D expense increased 8% to $22.2 million; selling, general and administrative expense rose 14% to $25.4 million, including higher intellectual-property legal costs, consulting and headcount expenses.
- For Q4 2016, revenue was $10.0 million versus $11.6 million in Q4 2015. Q4 2016 net loss was $5.3 million, compared with $2.1 million in Q4 2015. The 2016 fourth-quarter results included an approximately $0.3 million annual incentive-compensation true-up.
Outlook, risks and contingencies
- Management stated that existing cash, cash equivalents and marketable securities were expected to fund ongoing operations, planned capital expenditures and working capital for at least 12 months from the filing’s perspective. No specific revenue or earnings guidance was provided. Expected 2017 capital spending was approximately $1.0 million, mainly for laboratory-equipment replacement and upgrades.
- Codexis completed the GSK and Merck platform technology transfers in 2016. Potential future payments include GSK project-related contingent payments of $5.75 million to $38.5 million per project and Merck payments of up to $15.0 million for each qualifying commercial API; timing and achievement are uncertain.
- Growth initiatives include an exclusive December 2016 enzyme supply agreement with Tate & Lyle, a preclinical oral enzyme candidate for PKU, and an NGS enzyme expected to be available in beta-test format in Q2 2017. Commercial adoption, regulatory requirements and development outcomes remain uncertain.
- Customer concentration is significant: Merck contributed 47% and GSK 22% of 2016 revenue. The company also relies on a limited number of products and third-party manufacturers for large-scale enzyme production.
- Codexis filed an $80 million shelf registration statement in December 2016; it became effective in January 2017. Potential securities issuance could dilute existing shareholders.
- The company is pursuing litigation against EnzymeWorks and related defendants alleging patent infringement, trade-secret misappropriation and other claims. The outcome and timing were uncertain; no material litigation contingency amount is specified in the filing.
- Other risks include continuing losses, uncertain profitability, potential manufacturing interruptions, intellectual-property disputes, regulatory and commercialization hurdles, and the early-stage nature of the biotherapeutic program. The company reported no off-balance-sheet arrangements.
Most important facts for investors to verify
- How much of 2016 revenue and cash generation depended on Merck and GSK milestones, technology-transfer revenue and sitagliptin sales, and what recurring revenue remains after transfer completion.
- Whether product gross margins recover from 36% and whether customer and product concentration can be reduced.
- Cash burn, working-capital changes and the company’s stated minimum 12-month liquidity outlook, including the possible use of the $80 million shelf registration.
- Progress and commercial prospects for the Tate & Lyle supply agreement, the PKU candidate and the NGS enzyme beta test.
- Developments in the EnzymeWorks litigation and any material changes in manufacturing capacity, customer commitments or contingent-payment prospects.